Biliary tract cancer Clinical Trials
Recruiting biliary tract cancer studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.
Clinical trials study new ways to prevent, detect, or treat biliary tract cancer. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting biliary tract cancer studies with sites across the US; use the location tools to find ones near you.
What to expect
- Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
- Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
- No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.
Recruiting biliary tract cancer trials
EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis
Study of Occupational Risk Factors for Biliary and Pancreatic Cancers
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
TCR1188-ABC Cells in KRAS-mutated Cancers
BREATH RESEARCH NARROW VALIDATION FOR GASTROINTESTINAL CANCER DETECTION
Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Evaluation of Skin Tests in Biotherapy Allergies
Suprapapillary Metal Stent vs. Routine Transpapillary Drainage in Malignant Hilar Biliary Obstruction (SMART-B Trial)
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
Outcomes After Liver and Biliary Resection at a High-Volume Center
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers
Hepatobiliary and Pancreatic Tumor Biobank
Adjuvant Chemotherapy for BTC Based on 3D-PTA
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
PULSAR Combined With Immunotherapy and Chemotherapy
Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)
Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator
Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Streamlining Radioembolization for CCC and Metastatic Liver Cancer
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Biliary tract cancer clinical trials — common questions
Are biliary tract cancer clinical trials free to join?
Yes. Participating in a biliary tract cancer clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.
Who can join a biliary tract cancer clinical trial?
Each biliary tract cancer study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.
How do I find a biliary tract cancer trial near me?
Use the location controls above. We'll show recruiting biliary tract cancer trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.
How many biliary tract cancer trials are recruiting right now?
We're currently tracking roughly 64 recruiting biliary tract cancer trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.
Looking for a specific location? Browse trials by city and state.